MedPath

Study of vitamin K2-7(MK-7)levels in patients with tingling and numbness due to diabetes and/or vitamin B12 deficiency

Phase 4
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complicationsHealth Condition 2: D519- Vitamin B12 deficiency anemia, unspecified
Registration Number
CTRI/2019/06/019548
Lead Sponsor
Synergia Life Sciences Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Male and female aged 18 to 65 who are suffering from type 2 diabetes mellitus and/ or vitamin B12 deficiency.

2. Symptomatic diagnosis of neuropathy ( >4 on VAS score).

3. Willing to give informed consent

Exclusion Criteria

1. Patients who are suffering from any other systemic illness other than type 2 diabetes mellitus or vitamin B12 deficiency.

2. Patients who are on corticosteroids and oral contraceptives

3. Patients with seropositive status.

4. Pregnancy

5. Patients Participation in clinical trials evaluating investigational pharmaceuticals or biologics within 3 months or devices within 30 days of admission to the study.

6. Patients who are on coumarin analogues

7. Patients who are on Quinine Hydrochloride

8. History of alcohol. substance abuse or alcoholism, within the previous one year

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary objective of the study is to compare the activity and tolerability of Vitamin K2-7 with placebo in patients with peripheral neuropathy and to measure levels of vitamin K2-7 in serumTimepoint: 0 day, 2nd week, 4th week, 8th week, 12th week
Secondary Outcome Measures
NameTimeMethod
Safety and tolerability; clinical and metabolic variables.Timepoint: 0 day, 2nd week, 4th week, 8th week, 12th week
© Copyright 2025. All Rights Reserved by MedPath